Background NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine
that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (…

Background. Chickenpox, the primary infection caused by the Varicella Zoster virus, affects
more than 3 million children a year in the United States. Although usually self-limited, …

We compared the clinical presentation of 95 newborns with herpes simplex virus (HSV) infection
from 1973 through 1981 (first period) with data from 196 newborns evaluated from 1982 …

Background Improved influenza vaccines are needed to control seasonal epidemics. This
trial compared the protective efficacy in older adults of a quadrivalent, recombinant influenza …

In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …

Importance Greater than 20% of cases and 0.4% of deaths from COVID-19 occur in children.
Following demonstration of the safety and efficacy of the adjuvanted, recombinant spike …

… a b c d e f g h i k l m n , MD Harley A. Rotbart a b c d e f g h i k l m n , MD Sandor Feldman a
b c d e f g h i k l m n , MD Lisa M. Dunkle a b c d e f g h i k l m n , MD Henry M. Feder Jr. a b c …

2′,3′-didehydro-3′-deoxythymidine (d4T) is a pyrimidine analogue and inhibitor of reverse
transcriptase with potent in vitro activity against human immunodeficiency virus (HIV). A …

Background Expression of recombinant hemagglutinin (rHA) in insect cells represents a
technology with proven efficacy in seasonal influenza and with the potential for a rapid response …

• Medical records of 111 children discharged with the diagnosis of septic arthritis from 1973
through 1985 were examined; 122 infected joints were identified. Bacteria were isolated from …